Jump to Main Contents
研究所ロゴ

Home > Organization > Divisions and Independent Research Units > Laboratory of Integrative Oncology > Research Papers

Research Papers

 

2024年

  1. Yamaguchi K, Nakayama J, Yamamoto T, Semba K, Shirota T, Yamamoto Y. “Collagen induction of immune cells in the mammary glands during pregnancy.” Physiol Genomics, 1;56(2):128-135. (2024) [PubMed] 
  2. Nakamichi K, Yamamoto Y, Semba K, Nakayama J. “Metastatic potentials classified with hypoxia-inducible factor 1 downstream genes in pan-cancer cell lines.” Genes to Cells, 29(2):169-177. (2024)[PubMed] 
  3. Welsh JA, Goberdhan DCI, O'Driscoll L, Buzas EI, Blenkiron C, Bussolati B, Cai H, Di Vizio D, Driedonks TAP, Erdbrugger U, Falcon-Perez JM, Fu Q, Hill AF, Lenassi M, Lim SK, Mahoney MG, Mohanty S, Moller A, Nieuwland R, Ochiya T, Sahoo S, Torrecilhas AC, Zheng L, Zijlstra A, Bergese P, Bridges EM, Brucale M, Burger D, Carney RP, Cocozza F, Cocucci E, Colombo F, Crescitelli R, Hanser E, Harris AH, Haughey NJ, Hendrix A, Ivanov AR, Kruh-Garcia NA, Kyburz D, Lasser C, Lotvall J, Martens E, Mizenko RR, Newman LA, Ridolfi A, Rohde E, Rojalin T, Rowland A, Sandau U, Saugstad J, Shekari F, Swift S, Ter-Ovanesyan D, Tosar JP, Useckaite Z, Valle F, van Herwijnen MJC, Wauben MHM, Wehman AM, Williams S, Zendrini A, Zimmerman AJ, MISEV Consortium (including Yamamoto Y), Thery C & Witwer KW. “Minimal information for studies of extracellular vesicles (MISEV2023): from basic to advanced approaches.” Journal of Extracellular Vesicles. 13(2):e12404. (2024)[PubMed] 
  4. Kuroiwa Y, Ito K, Nakayama J, Semba K, Yamamoto Y. “Analysis of the responsiveness to antiandrogens in multiple breast cancer cell lines.” Genes to Cells, 29(4):301-315.(2024)[PubMed] 
  5. Nagao Y, Yokoi A, Yoshida K, Kitagawa M, Asano-Inami E, Kato T, Ishikawa M, Yamamoto Y, Kajiyama H. “Uterine leiomyosarcoma cell-derived extracellular vesicles induce the formation of cancer-associated fibroblasts.” BBA - Molecular Basis of Disease, 1870(4):167103. (2024)[PubMed] 
  6. Uehara T, Matsuzaki J, Yoshida H, Ogawa Y, Miura J, Fujimiya H, Yamamoto Y, Kawauchi J, Takizawa S, Yonemori K, Sakamoto H, Kato K, Ishikawa M, Ochiya T. “Potential utility of pretreatment serum miRNAs for optimal treatment selection in advanced high-grade serous ovarian cancer.” Jpn J Clin Oncol, 54(8):917-925. (2024)[PubMed]
  7. Prieto-Vila M, Yoshioka Y, Kuriyama N, Okamura A, Yamamoto Y, Muranaka A, Ochiya T. “Adult cardiomyocytes-derived EVs for the treatment of cardiac fibrosis.” J Extracell Vesicles, 13(7):e12461. (2024)[PubMed] 
  8. Yamamoto T, Nakayama J, Urabe F, Ito K, Nishida-Aoki N, Kitagawa M, Yokoi A, Kuroda M, Hattori Y, Yamamoto Y & Ochiya. “Aberrant regulation of serine metabolism drives extracellular vesicle release and cancer progression.” Cell Reports, 43(8):114517. (2024)[PubMed] 
  9. Shibata M, Yoshida K, Yokoi A, Suzuki H, Yamamoto Y, Kitagawa M, Asano-Inami E, Yasui Y, Nishiko Y, Yoshihara M, Tamauchi S, Yoshikawa N, Nishino K, Yamamoto E.“Elucidation of the role of XBP1 in the progression of complete hydatidiform mole to invasive mole through RNA-seq.”Gynecologic Oncology,190:189-199.(2024)  [PubMed]

2023年

  1.  Urabe F, Kosaka N, Yamamoto Y, Ito K, Otsuka K, Soekmadji C, Kimura T, Egawa S, & Ochiya T. “Metastatic prostate cancer-derived extracellular vesicles facilitate osteoclastogenesis by transferring the CDCP1 protein.” Journal of Extracellular Vesicles, 12(3):e12312. (2023)  [PubMed]

  2. Nagao Y, Yokoi A, Yoshida K, Sugiyama M, Watanabe E, Nakamura K, Kitagawa M, Asano-Inami E, Koya Y, Yoshihara M, Tamauchi S, Shimizu Y, Ikeda Y, Yoshikawa N, Kato T, Yamamoto Y, Kajiyama H. “Novel therapeutic strategies targeting UCP2 in uterine leiomyosarcoma.” Pharmacological Research, 189:106693.  (2023)  [PubMed]

  3. Yoshida K, Yokoi A, Kitagawa M, Sugiyama M, Yamamoto T, Nakayama J, Yoshida H, Kato T, Kajiyama H, Yamamoto Y. “Downregulation of miR‑10b‑5p facilitates the proliferation of uterine leiomyosarcoma cells: A microRNA sequencing‑based approach.” Oncology Reports, 49(5):86.  (2023)  [PubMed]

  4. Hayashi Y, Nakayama J, Yamamoto M, Maekawa M, Watanabe S, Higashiyama S, Inoue JI, Yamamoto Y, Semba K. Aberrant accumulation of NIK promotes tumor growth by dysregulating translation and post-translational modifications in breast cancer. Cancer Cell Int, 1;23(1):57. (2023) [PubMed] 

  5. Suzuki K, Yokoi A, Yoshida K, Kato T, Ochiya T, Yamamoto Y, Kajiyama H. “Preoperative serum microRNAs as potential prognostic biomarkers in ovarian clear cell carcinoma.” J Gynecol Oncol, 34(3):e34.(2023) [PubMed]

  6. Chang X, Tamauchi S, Yoshida K, Yoshihara M, Yokoi A, Shimizu Y, Ikeda Y, Yoshikawa N, Kiyono T, Yamamoto Y, Kajiyama H. Downregulating vaccinia-related kinase 1 by luteolin suppresses ovarian cancer cell proliferation by activating the p53 signaling pathway. Gynecol Oncol, (IF: 5.48; Q2).173:31-40.(2023) [PubMed] 

  7. Yokoi A, Ukai M, Yasui T, Inokuma Y, Hyeon-Deuk K, Matsuzaki J, Yoshida K, Kitagawa M, Chattrairat K, Iida M, Shimada T, Manabe Y, Chang IY, Asano-Inami E, Koya Y, Nawa A, Nakamura K, Kiyono T, Kato T, Hirakawa A, Yoshioka Y, Ochiya T, Hasegawa T, Baba Y, Yamamoto Y, Kajiyama H. Identifying high-grade serous ovarian carcinoma-specific extracellular vesicles by polyketone-coated nanowires. Sci Adv,  (IF: 14.14; Q1).9(27):eade6958. (2023) [PubMed]

  8. Shiino S, Tokura M, Nakayama J, Yoshida M, Suto A, Yamamoto Y. Investigation of Tumor Heterogeneity Using Integrated Single-Cell RNA Sequence Analysis to Focus on Genes Related to Breast Cancer-, EMT-, CSC-, and Metastasis-Related Markers in Patients with HER2-Positive Breast Cancer. Cells, 15;12(18):2286. (2023) [PubMed] 

  9. Ito K, Yamamoto T, Hayashi Y, Sato S, Nakayama J, Urabe F, Shimasaki T, Nakamura E, Matui Y, Fujimoto H, Kimura T, Egawa S, Ochiya T, Yamamoto Y. Osteoblast-derived extracellular vesicles exert osteoblastic and tumor-suppressive functions via SERPINA3 and LCN2 in prostate cancer. Mol Oncol, 17(10):2147-2167. (2023) [PubMed] 

  10. Suzuki H, Yokoi A, Uno K, Yoshida K, Kitagawa M, Asano-Inami E, Matsuo S, Nagao Y, Suzuki K, Nakamura K, Yoshihara M, Tamauchi S, Shimizu Y, Ikeda Y, Yoshikawa N, Kajiyama H, Yamamoto Y. Small Extracellular Vesicles from adipose-derived stem cells suppress cell proliferation by delivering the let-7 family of microRNAs in ovarian cancer. Biochem Biophys Res Commun, 5;680:211-219. (2023) [PubMed]

  11. Nakayama J, Yamamoto Y. Cancer-prone Phenotypes and Gene Expression Heterogeneity at Single-cell Resolution in Cigarette-smoking Lungs.Cancer Res Commun. 10;3(11):2280-2291. (2023) [PubMed] 

  12. Yokoi A, Yoshida K, Koga H, Kitagawa M, Nagao Y, Iida M, Kawaguchi S, Zhang M, Nakayama J, Yamamoto Y, Baba Y, Kajiyama H, Yasui T. Spatial exosome analysis using cellulose nanofiber sheets reveals the location heterogeneity of extracellular vesicles. Nat Commun, 8;14(1):6915. (2023) [PubMed]

2022年

  1. Suzuki K, Yamaguchi T, Tanaka M, Kohda M, Takemura H, Wakita M, Tabe Y, Kato S, Nasu M, Hashimoto T, Mine S, Serizawa N, Tomishima K, Nagahara A, Matsuda T, Yamaji T, Tsugane S, Saito Y, Daiko H, Yoshikawa T, Kato K, Okusaka T, Ochiya T, Yamamoto Y, Yotsui S, Yamamoto T, Yamasaki T, Miyata H, Yasui M, Omori T, Ohkawa K, Ikezawa K, Nakabori T, Sugimoto N, Kudo T, Yoshida K, Ohue M, Nishizawa T. “Establishment of preanalytical conditions for microRNA profile analysis of clinical plasma samples.” PLOS One, 17(12):e0278927. (2022) [PubMed] 　 
  2. Zhang Y, Goto Y, Yagishita S, Shinno Y, Mizuno K, Watanabe N, Yamamoto Y, Ota N, Ochiya T, Fujita Y. “Machine Learning-based Exceptional Response Prediction of Nivolumab Monotherapy with Circulating MicroRNAs in Non-Small Cell Lung Cancer.” Lung Cancer, 173:107-115. (2022) [PubMed] 
  3. Watanabe N, Fujita Y, Nakayama J, Mori Y, Hayashi Y, Kadota T, Shimomura I, Otsuka T, Okamoto K, Araya J, Kuwano K, Yamamoto Y. “Anomalous Epithelial Variations and Ectopic Inflammatory Response in Chronic Obstructive Pulmonary Disease.” Am J Respir Cell Mol Biol, 67(6):708-719. (2022) [PubMed]　 
  4. Urabe F, Yamamoto Y, Kimura T. “miRNAs in prostate cancer: intercellular and extracellular communications.” International Journal of Urology, 29(12):1429-1438. (2022) [PubMed]
  5. Watanabe E, Yokoi A, Yoshida K, Sugiyama M, Kitagawa M, Nishino K, Yamamoto E, Niimi K, Yamamoto Y, Kajiyama H. “Drug library screening identifies histone deacetylase inhibition as a novel therapeutic strategy for choriocarcinoma.” Cancer Med, 12(4):4543-4556. (2022) [PubMed]
  6. Yamamoto T, Yamamoto Y, Ochiya T. “Extracellular vesicle-mediated immunoregulation in cancer.” International Journal of Hematology,117(5):640-646.  (2022) [PubMed]
  7. Prieto-Vila M, Usuba W, Yoshioka Y, Takeshita F, Yoshiike M, Sasaki H, Yamamoto Y, Kikuchi E, Ochiya T. “High-grade bladder cancer cells secrete extracellular vesicles containing miRNA-146a-5p and promotes angiogenesis.“ Journal of Extracellular Biology, 1:e47. (2022)  

  8. Tokura M, Nakayama J, Prieto-Vila M, Shiino S, Yoshida M, Yamamoto T, Watanabe N, Takayama S, Suzuki Y, Okamoto K, Ochiya T, Kohno T, Yatabe Y, Suto A, Yamamoto Y. “Single-Cell Transcriptome Profiling Reveals Intratumoral Heterogeneity and Molecular Features in Ductal Carcinoma In Situ.“ Cancer Research, 16;82(18):3236-3248. (2022) [PubMed]

  9. Nakayama J, Matsunaga H, Arikawa K, Yoda T, Hosokawa M, Takeyama H, Yamamoto Y, Semba K. “Identification of two cancer stem cell-like populations in triple-negative breast cancer xenografts.“ Dis Model Mech, 15(6):dmm049538 (2022) [PubMed]

  10. Yoshida K, Yokoi A, Yamamoto T, Hayashi Y, Nakayama J, Yokoi T, Yoshida H, Kato T, Kajiyama H, Yamamoto Y. “Aberrant activation of cell cycle-related kinases and the potential therapeutic impact of PLK1 or CHEK1 inhibition in uterine leiomyosarcoma.“ Clinical Cancer Research, 28(10):2147-2159 (2022) [PubMed]

  11. Urabe F, Matsuzaki J, Ito K, Takamori H, Tsuzuki S, Miki J, Kimura T, Egawa S, Nakamura E, Matsui Y, Fujimoto H, Yamamoto Y, Ochiya T. “Serum miRNAs as liquid biopsy biomarker for the prediction of oncological outcomes in patients with bladder cancer.“ International Journal of Urology, 29(9):968-976. (2022) [PubMed]

  12. Suzuki K, Igata H, Abe M, Yamamoto Y, Small RNA cancer screening project. “Multiple cancer type classification by small RNA expression profiles with plasma samples from multiple facilities.“ Cancer Science, 113(6):2144-2166 (2022) [PubMed]

  13. Yamaguchi K, Yamamoto T, Chikuda J, Shirota T, Yamamoto Y. “Impact of non-coding RNAs on chemotherapeutic resistance in oral cancer.“ Biomolecules, 12(2):284. (2022) [PubMed]

  14. Yamamoto T, Nakayama J, Yamamoto Y, Kuroda M, Hattori Y, & Ochiya T. “SORT1/LAMP2-mediated Extracellular Vesicle Secretion and Cell Adhesion Are Linked to Drug Resistance in Multiple Myeloma.“ Blood Advances, 6(8):2480-2495 (2022) [PubMed]

2021

  1. Yoshida K, Yokoi A, Matsuzaki J, Kato T, Ochiya T, Kajiyama H, Yamamoto Y. “Extracellular microRNA profile for prognostic prediction in patients with high-grade serous ovarian carcinoma.“ Cancer Science, 112(12):4977-4986. (2021) [PubMed]
  2. Shimomura I, Watanabe N, Yamamoto T, Kumazaki M, Tada Y, Tatsumi K, Ochiya T & Yamamoto Y. “Selective targeting of KRAS-driven lung tumorigenesis via unresolved ER stress.“ JCI Insight, 6(7): e137876. (2021) [PubMed]
  3. Yoshida K, Yokoi A, Yamamoto Y, Kajiyama H. “ChrXq27.3 miRNA cluster functions in cancer development.” J Exp Clin Cancer Res. 40(1):112. (2021) [PubMed]
  4. Watase C, Shiino S, Shimoi T, Noguchi E, Kaneda T, Yamamoto Y, Yonemori K, Takayama S, Suto A. “Breast Cancer Brain Metastasis—Overview of Disease State, Treatment Options and Future Perspectives.” Cancers (Basel). 13(5), 1078. (2021) [PubMed]
  5. Nakayama J, Han Y, Kuroiwa Y, Azuma K, Yamamoto Y, Semba K. “The in vivo selection method in breast cancer metastasis.” IJMS, 22(4): 1886. (2021) [PubMed]
  6. Yoshida K, Yamamoto Y, Ochiya T. “miRNA signaling networks in cancer stem cells.” Regen Ther. 17 :1-7. (2021) [PubMed]
  7. Zhou Y, Yamamoto Y, Takeshita F, Yamamoto T, Xiao Z, Ochiya T. “Delivery of miR-424-5p via Extracellular Vesicles Promotes the Apoptosis of MDA-MB-231 TNBC Cells in the Tumor Microenvironment.” Int J Mol Sci. 22(2):844. (2021) [PubMed]
  8. Hashimoto K, Inada M, Yamamoto Y & Ochiya T. “Preliminary evaluation of miR-1307-3p in human serum for detection of 13 types of solid cancer using microRNA chip.“ Heliyon, 7(9):e07919. (2021) [PubMed]
  9. Harada K, Sakamoto N, Ukai S, Yamamoto Y, Thang PQ, Taniyama D, Honma R, Maruyama R, Takashima T, Ota H, Takemoto Y, Tanabe K, Ohdan H, Yasui W. “Establishment of oxaliplatin-resistant gastric cancer organoids: importance of myoferlin in the acquisition of oxaliplatin resistance.“ Gastric Cancer, 24(6):1264-1277. (2021) [PubMed]
  10. Kadota T, Fujita Y, Araya J, Watanabe N, Fujimoto S, Kawamoto H, Minagawa S, Hara H, Otsuka T, Yamamoto Y, Kuwano K & Ochiya T. “Human bronchial epithelial cell-derived extracellular vesicle therapy for pulmonary fibrosis via inhibition of TGF-β-WNT crosstalk.“ JEV, 10(10):e12124. (2021) [PubMed]
  11. Yano K, Takahashi RU, Shiotani B, Abe J, Shidooka T, Sudo Y, Yamamoto Y, Kan S, Sakagami H, Tahara H. “PRPF19 regulates p53-dependent cellular senescence by modulating alternative splicing of MDM4 mRNA.“ JBC, 297(1):100882. (2021) [PubMed]
  12. Urabe F, Kimura T, Ito K, Yamamoto Y, Tsuzuki S, Miki J, Ochiya T, Egawa S.  “Urinary extracellular vesicles: a rising star in bladder cancer management. “ Transl Androl Urol. 10(4):1878-1889. (2021) [PubMed]
  13. Kohama I, Asano N, Matsuzakia J, Yamamoto T, Yamamoto Y, Takahashi RU, Kobayashi E, Kawai A, Takizawa S, Sakamoto H, Chikuda H & Ochiya T.  “Comprehensive miRNA profiling between serum and tissue in Dedifferentiated liposarcoma. “ Oncology letters, 22(2):623. (2021) [PubMed]

2020年

  1. Otsuka K, Yamamoto Y, Ochiya T. “Uncovering temperature-dependent extracellular vesicle secretion in breast cancer.” J Extracell Vesicles. 10(2):e12049. (2020)[PubMed]
  2. Ukai S, Honma R, Sakamoto N, Yamamoto Y, Pham QT, Harada K, Takashima T, Taniyama D, Asai R, Fukada K, Naka K, Tanabe K, Ohdan H, Yasui W. “Molecular biological analysis of 5-FU-resistant gastric cancer organoids; KHDRBS3 contributes to the attainment of features of cancer stem cell.” Oncogene. 39(50):7265-7278. (2020) [PubMed]
  3. Ichikawa A, Fujita Y, Hosaka Y, Kadota T, Ito A, Yagishita S, Watanabe N, Fujimoto S, Kawamoto H, Saito N, Yoshida M, Hashimoto M, Minagawa S, Hara H, Motoi N, Yamamoto Y, Ochiya T, Araya J, Kuwano K. “Chaperone-mediated autophagy receptor modulates tumor growth and chemoresistance in non-small cell lung cancer.” Cancer Sci. 111(11):4154-4165. (2020) [PubMed]
  4. Yoshida K, Yokoi A, Kato T, Ochiya T, Yamamoto Y. “The clinical impact of intra- and extracellular miRNAs in ovarian cancer.” Cancer Sci. 2020;111(10):3435-3444.[PubMed]
  5. Urabe F, Kosaka N, Sawa Y, Ito K, Kimura T, Egawa S, Ochiya T, Yamamoto Y. “The miR-1908/SRM regulatory axis contributes to extracellular vesicle secretion in prostate cancer.” Cancer Sci. 111(9):3258-3267. (2020)[PubMed]
  6. Kogure A, Naito Y, Yamamoto Y, Yashiro M, Kiyono T, Yanagihara K, Hirakawa K, Ochiya T. “Cancer cells with high-metastatic potential promote a glycolytic shift in activated fibroblasts.” PLoS One. 15(6):e0234613. (2020)[PubMed]
  7. Prieto-Vila M, Shimomura I, Kogure A, Usuba W, Takahashi RU, Ochiya T & Yamamoto Y. “Quercetin inhibits Lef1 and resensitize docetaxel-resistant breast cancer cells.” Molecules, 25(11): E2576. (2020) [PubMed]
  8. Calle AS, Yamamoto T, Kawamura Y, Mitsuhashi-Hironaka A, Ono M, Tsuda H, Tamura K, Shimomura A, Takeshita F, Ochiya T & Yamamoto Y. “Long Non-coding NR2F1-AS1 is Associated with Tumor Recurrence in Estrogen Receptor-positive breast cancers.” Molecular Oncology, 14(9):2271-2287. (2020) [PubMed]
  9. Kurashima K, Kashiwagi H, Shimomura I, Suzuki A, Takeshita F, Mazevet M, Harata M, Yamashita T, Yamamoto Y, Kohno T & Shiotani B. “SMARCA4 defects-associated heterochromatin induces intrinsic DNA replication stress and vulnerability to ATR inhibition in lung adenocarcinoma.” NAR Cancer, 2(2): zcaa005. (2020)
  10. Chikuda J, Otsuka K, Shimomura I, Miyazaki H, Takahashi RU, Mukudai Y, Ochiya T, Shimane T, Shirota T & Yamamoto Y. “CD44s Induces miR-629-3p Expression Associated with Cisplatin Resistance in Head and Neck Cancer Cells.” Cancers, 12(4). pii: E856. (2020) [PubMed]
  11. Tadokoro H, Hirayama A, Kudo R, Hasebe M, Yoshioka Y, Matsuzaki J, Yamamoto Y, Sugimoto M, Soga T & Ochiya T. “Adenosine leakage from perforin-burst extracellular vesicles inhibits perforin secretion by cytotoxic T-lymphocytes.” Plos ONE, 15(4): 231430. (2020) [PubMed]
  12. Asakura K, Kadota T, Matsuzaki J, Yoshida Y, Yamamoto Y, Nakagawa K, Takizawa S, Aoki Y, Nakamura E, Miura J, Sakamoto H, Kato K, Watanabe SI & Ochiya T. “A miRNA-based Diagnostic Model Predicts Resectable Lung Cancer in Humans With High Accuracy.” Communications Biology, 3(1):134. (2020) [PubMed]
  13. Kumazaki M, Shimomura I, Kiyono T, Ochiya T, & Yamamoto Y. “Cell-type specific Tumorigenesis with Ras Oncogenes in Human Lung Epithelial Cells.” BBRC, 525(2):483-490. (2020) [PubMed]
  14. Prieto-Vila M, Ochiya T & Yamamoto Y. “Single-cell qPCR assay with massively parallel microfluidic system. ” Bio-protocol,10(6): e3563. (2020)[PubMed]
  15. Urabe F, Kosaka N, Sawa Y, Yamamoto Y, Ito K, Yamamoto T, Kimura T, Egawa S, Ochiya T. “miR-26a regulate the extracellular vesicle secretion from prostate cancer cells via targeting PFDN4, CHORDC1 and SHC4. ” Science Advances, 6, eaay3051. (2020) [PubMed]
  16. Duleba M, Yamamoto Y (co-first), Qi Y, Neupane R, Rao W, Liew A, Niroula S, Zhang Y, Xie J, Mahalingam R, Wang S, Goller K, Vincent M, Ho KY, Hou JK, Hyams JS, Sylvester FA, Crum CP, McKeon F & Xian W. “Cloning of Ground State Intestinal Stem Cells (gISC) from Endoscopic Biopsies.” Nature Protocols, 15(5): 1612-1627. (2020) [PubMed]
  17. Hironaka-Mitsuhashi A, Otsuka K, Galhouste L, Yamamoto Y, Fujiwara Y & Ochiya T. “miR-1285-5p/TMEM194A axis contributes to cell proliferation in breast cancer.” Cancer Science, 111: 395-405. (2020) [PubMed]
  18. Yoshihara M, Kajiyama H, Yokoi A, Sugiyama M, Koya Y, Yamakita Y, Liu W, Nakamura K, Moriyama Y, Yasui H, Suzuki S, Yamamoto Y, Ricciardelli C, Nawa A, Shibata K & Kikkawa F. “Ovarian cancer-associated mesothelial cells induce acquired platinum-resistance in peritoneal metastasis via the FN1/Akt signaling pathway.” International Journal of Cancer, 146: 2268-2280 (2020) [PubMed]
  19. Yamamoto Y, Kondo S, Matsuzaki J, Esaki M, Okusaka T, Shimada K, Murakami Y, Enomoto M, Tamori A, Kato K, Aoki Y, Ichikawa M, Takizawa S, Sakamoto H, Niida S, Takeshita F & Ochiya T. “Highly Sensitive Circulating MicroRNA Panel for Accurate Detection of Hepatocellular Carcinoma in Patients With Liver Disease.” Hepatology Communications, 4: 284-297 (2020) [PubMed]
  20. Liew LC, Gailhouste L, Tan GC, Yamamoto Y, Takeshita F, Nakagama H & Ochiya T. “MicroRNA-124a Inhibits Endoderm Lineage Commitment by targeting Sox17 and Gata6 in Mouse Embryonic Stem Cells.” Stem Cells, 38(4):504-515. (2020) [PubMed]

2019年

  1. Yokoi A, Matsuzaki J, Yamamoto Y, Tate K, Yoneoka Y, Shimizu H, Uehara T, Ishikawa M, Takizawa S, Aoki Y, Kato K, Kato T & Ochiya T. “Serum microRNA profile enables preoperative diagnosis for uterine leiomyosarcoma. ” Cancer sci., 110 : 3718-3726. (2019) [PubMed]
  2. Sato J, Shimomura A, Kawauchi J, Matsuzaki J, Yamamoto Y, Takizawa S, Sakamoto H, Ohno M, Narita Y, Ochiya T & Tamura K. “Brain metastasis-related microRNAs in patients with advanced breast cancer.” Plos ONE, 14: e0221538. (2019) [PubMed]
  3. Tsushita-Satomi N, Shimomura A, Matsuzaki J, Yamamoto Y, Kawauchi J, Takizawa S, Aoki Y, Sakamoto H, Shimizu C, Ochiya T & Tamura K. “Serum MiRNA-based Prediction for Responsiveness to Eribulin in Metastatic Breast Cancer.” Plos ONE, 14: e0222024. (2019) [PubMed]
  4. Zhou Y, Yamamoto Y, Xiao Z & Ochiya T. “The immunomodulatory function of mesenchymal stromal/stem cells via paracrine activity.” J Clin Med. 8(7). pii: E1025. (2019) [PubMed]
  5. Kawamura Y, Calle AS, Yamamoto Y, Sato T & Ochiya T. “Extracellular vesicles mediate extracellular export and horizontal transfer of an active LINE-1 retrotransposon.” JEV, 8: 1643214. (2019) [PubMed]
  6. Prieto-Vila M, Usuba W, Takahashi RU, Shimomura I, Sasaki H, Ochiya T & Yamamoto Y. “Single-cell Analysis Reveals a Preexisting Drug Resistant subpopulation in Breast Cancer Cells.” Cancer Research, 79:4412-4425. (2019) [PubMed]
  7. Naito Y, Yamamoto Y, Sakamoto N, Shimomura I, Kogure A, Kumazaki M, Yashiro M, Kiyono T, Yanagihara K, Takahashi RU, Hirakawa K, Yasui W & Ochiya T. “Cancer Extracellular Vesicles Contribute to Stromal Heterogeneity by Inducing Chemokines in Cancer-Associated Fibroblasts.” Oncogene, 38(28):5566-5579. (2019) [PubMed]
  8. Shimomura I, Yamamoto Y & Ochiya T. “Synthetic Lethality in Lung Cancer - From the Perspective of Cancer Genomics.” Medicines, 6(1) (2019) [PubMed]
  9. Sonoda T, Matsuzaki J, Yamamoto Y, Aoki Y, Takizawa S, Niida S & Ochiya T. “Serum miRNA-based risk prediction for stroke.” Stroke, 50(6):1510-1518. (2019) [PubMed]
  10. Xian W, Duleba M, Zhang Y, Yamamoto Y, Ho KY, Crum CP & McKeon F. “The Cellular Origin of Barrett’s Esophagus and Its Stem Cells.” Adv Exp Med Biol. Review, 1123 : 55-69. (2019) [PubMed]
  11. Shimomura I, Yokoi A, Kumazaki M, Tada Y, Tatsumi K, Ochiya T & Yamamoto Y. “Drug Library Screen Reveals Benzimidazole Derivatives as Selective Cytotoxic Agents for KRAS-mutant Lung Cancer.” Cancer Letters, 451:11-22. (2019) [PubMed]
  12. Urabe F, Matsuzaki J, Yamamoto Y, Hara T, Kimura T, Takizawa S, Aoki Y, Niida S, Sakamoto H, Kato K, Egawa S, Fujimoto H & Ochiya T. “Large-scale Circulating microRNA Profiling for the Liquid Biopsy of Prostate Cancer.” Clinical Cancer Research, 25(10):3016-3025. (2019) [PubMed]

2018年

  1. Xian W, Duleba M, Yamamoto Y, Vincent M & McKeon F. “Biobanking Organoids or Ground-State Stem Cells? ”J Clin Med., 7(12) (2018) [PubMed]
  2. Usuba W, Urabe F, Yamamoto Y(co-first), Matsuzaki J, Sasaki H, Hara T, Takizawa S, Aoki Y, Niida S, Sakamoto H, Sudo K, Kato K, Chikaraishi T, Fujimoto H & Ochiya T. “Circulating miRNA Panels for Specific and Early Detection in Bladder Cancer.” Cancer sci., 110(1): 408-419. (2018) [PubMed]
  3. Yokoi A, Matsuzaki J, Yamamoto Y, Takahashi K, Shimizu H, Uehara T, Ishikawa M, Ikeda S, Takizawa S, Aoki Y, Sakamoto H, Kato K, Kato T & Ochiya T. “Integrated extracellular miRNA profiling for ovarian cancer screening.” Nat. Commun., 9(1):4319 (2018) [PubMed]
  4. Calle AS, Kawamura Y, Yamamoto Y, Takeshita F & Ochiya T. “The emerging roles of long non-coding RNA in cancer.” Cancer sci., 109: 2093-2100 (2018) [PubMed]
  5. Naito Y, Hamada-Tsutsumi S, Yamamoto Y, Kogure A, Yoshioka Y, Watashi K, Ochiya T & Tanaka Y. “Screening of microRNAs as a repressor of Hepatitis B virus replication.” Oncotarget, 9: 29857-29868 (2018) [PubMed ]
  6. Otsuka K, Yamamoto Y & Ochiya T. “Regulative role of a microRNA-controlling compound, resveratrol, in HNRNPA1 expression that is associated with poor prognosis in breast cancer.” Oncotarget, 9: 24718-24730 (2018) [PubMed]
  7. Zhou Y, Yamamoto Y, Itaya T, Xiao Z & Ochiya T. “Distinct miRNA expression patterns of extracellular vesicles derived from 4 types of mesenchymal stem cells. ” J Stem Cell Res Ther., 8: 415 (2018)
  8. Hironaka-Mitsuhashi A, Matsuzaki J, Takahashi RU, Yoshida M, Nezu Y, Yamamoto Y, Shiino S, Kinoshita T, Ushijima T, Hiraoka N, Shimizu C, Tamura K & Ochiya T. “A tissue microRNA signature to predict breast cancer recurrence in young women.” PLoS ONE, 12(11): e0187638 (2017) [PubMed]
  9. Otsuka K, Yamamoto Y, Matsuoka R & Ochiya T. “Maintaining a good miRNA profile in the body keeps the doctor away?: An Overview of the Relationship between Food-Derived Natural Products, microRNAs, and Exosomes/Extracellular Vesicles.” Mol Nutr Food Res. 62(1) (2018) [PubMed]
  10. Shimagaki T, Yoshizumi T, Harimoto N, Yoshio S, Naito Y, Yamamoto Y, Ochiya T, Yoshida Y, Kanto T & Maehara Y. “MicroRNA-125b expression and intrahepatic metastasis are predictors for early recurrence after hepatocellular carcinoma resection.” Hepatology research, 48(4): 313-321 (2018) [PubMed]

2017年

  1. Yokoi A, Yoshioka Y, Hirakawa A, Yamamoto Y, Ishikawa M, Ikeda S, Kato T, Niimi K, Kajiyama H, Kikkawa F & Ochiya T. “A combination of circulating miRNAs for the early detection of ovarian cancer.” Oncotarget 8(52):89811-89823. (2017) [PubMed]
  2. Basuli D, Tesfay L, Deng Z, Paul B, Yamamoto Y, Ning G, Xian W, McKeon F, Lynch M, Crum CP, Hegde P, Brewer M, Wang X, Miller L, Dyment N, Torti FM & Torti SV. “Iron addiction: A novel therapeutic target in ovarian cancer.” Oncogene, 36(29): 4089-4099. (2017) [PubMed]
  3. Kawamura Y, Yamamoto Y, Sato T & Ochiya T. “Extracellular vesicles as trans-genomic agents: emerging roles in disease and evolution.” Cancer sci. 108: 824-830, (2017) [PubMed]
  4. Yokoi A, Yoshioka Y, Yamamoto Y, Ishikawa M, Ikeda S, Kato T, Kiyono T, Kajiyama H, Kikkawa F & Ochiya T. “Malignant extracellular vesicles carrying MMP1 mRNA facilitate peritoneal dissemination in ovarian cancer.” Nat. Commun., 8 : 14470, (2017) [PubMed]
  5. Yamamoto Y & Ochiya T. “Epithelial stem cell culture: modeling human disease and applications for regenerative medicine.” Regeneration and inflammation, Review, 37 : 3, (2017) [PubMed]
  6. Katsuda T, Kawamata M, Hagiwara K, Takahashi RU, Yamamoto Y, Camargo FD & Ochiya T. “Conversion of terminally committed hepatocytes to culturable bipotent progenitor cells with regenerative capacity.” Cell Stem Cell, 20(1) : 41-55 (2017) [PubMed]
  7. Naito Y, Yoshioka Y, Yamamoto Y & Ochiya T. “How cancer cells dictate their microenvironment: present roles of extracellular vesicles.” Cell Mol Life Sci., Review, 74: 697-713, (2017) [PubMed]

2016年

  1. Nezu Y, Hagiwara K, Yamamoto Y, Fujiwara T, Matsuo K, Yoshida A, Kawai A, Saito T & Ochiya T. “miR-135b, a key regulator of malignancy, is linked to poor prognosis in human myxoid liposarcoma.” Oncogene, 35 (48):6177-6188 (2016) [PubMed]
  2. Yamamoto Y, Wang X, Bertrand D, Kern F, Zhang T, Duleba M, Srivastava S, Khor CC, Hu Y, Wilson L, Blaszyk H, Rolshud D, The M, Liu J, Howitt BE, Vincent M, Crum CP, Nagarajan N, Ho KY, McKeon F & Xian W. “Mutational Spectrum of Barrett’s Stem Cells Suggests Paths to Initiation of a Precancerous Lesion.” Nat. Commun., 7: 10380. (2016) [PubMed]
  3. Yamamoto Y, Ning G, Howitt BE, Mehra K, Wu L, Wang X, Hong Y, Kern F, Tay SW, Zhang T, Nagarajan N, Basuli D, Torti S, Brewer M, Choolani M, McKeon F, Crum CP & Xian W. “In Vitro and In Vivo Correlates of Physiologic and Neoplastic Human Fallopian Tube Stem Cells.” J Pathol., 238(4): 519-530. (2016) [PubMed]

2015年

  1. Takahashi RU, Miyazaki H, Takeshita F, Yamamoto Y, Minoura K, Ono M, Kodaira M, Tamura K, Mori & Ochiya T. “Loss of microRNA-27b contributes to breast cancer stem cell generation by activating ectonucleotide pyrophosphatase 1.” Nat. Commun., 6: 7318 (2015) [PubMed]
  2. Wang X, Yamamoto Y (co-first), Wilson LH, Zhang T, Howitt B, Farrow MA, Kern F, Ning G, Hong Y, Khor CC, Chevalier B, Bertrand D, Nagarajan N, Sylvester FA, Hyams JS, Devers T, Bronson R, Lacy DB, Ho KY, Crum CP, McKeon F & Xian W. “Cloning and Variation of Ground State Intestinal Stem Cells.” Nature, 522 (7555): 173-178. (2015) [PubMed]
  3. Fujita Y, Yagishita S, Takeshita F, Yamamoto Y, Kuwano K & Ochiya T. “Prognostic and therapeutic impact of RPN2-mediated tumor malignancy in non-small-cell lung cancer,” Oncotarget, 6(5): 3335-3345. (2015) [PubMed]
  4. Zuo W, Wu DZ, Zhang T, Guan SP, Liew A, Yamamoto Y, Vincent M, Lessard M, Crum CP, Wang X, Lim SJ, Xian W & McKeon F. “p63+/Krt5+ Distal Airway Stem Cells are Essential for Lung Regeneration,” Nature, 517 (7536): 616-620. (2015) [PubMed]
  • Our Research Focus